Institutional Fund
Caligan Partners LP
New York, NYCIK 17274925 filings on record
Portfolio Value
$1.41B
Q1 2026
Holdings
24
Reported positions
New Buys
8
Opened this quarter
QoQ Change
+29.4%
from $1.09B
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- Liquidia Corporation21.7%
- Abivax SA11.5%
- Revolution Medicines Inc11.4%
- Vaxcyte Inc8.5%
- Xenon Pharmaceuticals Inc5.7%
- Mineralys Therapeutics Inc5.3%
- Other35.9%
Portfolio Holdings
24 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Liquidia Corporation | 8.12M | $306.41M | 21.7% | 0 | Held |
| 2 | Abivax SA | 1.46M | $162.79M | 11.5% | +10.0K | Added |
| 3 | Revolution Medicines Inc | 1.65M | $160.74M | 11.4% | +368.9K | Added |
| 4 | Vaxcyte Inc | 2.06M | $119.75M | 8.5% | +355.9K | Added |
| 5 | Xenon Pharmaceuticals Inc | 1.39M | $81.00M | 5.7% | +843.4K | Added |
| 6 | Mineralys Therapeutics Inc | 2.77M | $75.11M | 5.3% | 0 | Held |
| 7 | Exelixis Inc | 1.55M | $66.62M | 4.7% | 0 | Held |
| 8 | Tango Therapeutics Inc | 2.41M | $50.39M | 3.6% | −1.32M | Reduced |
| 9 | Tyra Biosciences Inc | 1.28M | $48.91M | 3.5% | +332.7K | Added |
| 10 | Spyre Therapeutics Inc | 878.1K | $44.29M | 3.1% | +878.1K | New |
14 more holdings on Premium
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio